Ollin Biosciences

Biotech developing OLN324, a biologic entering Phase 3 trials for diabetic macular edema and wet age-related macular degeneration.

View on the globe

$430MEquity raised in 2025–20262025 $100M · 2026 $330M · 2 equity rounds
$430MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from 17 Sep 2025 to 24 Jun 2026, $430M equity disclosed. Earlier rounds exist but are not sourced.17 Sep 2025: Launch financing, $100M; 24 Jun 2026: Series B, $330M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 2023Q3Q42026Q2Q3Q4Equity round24 Jun 2026 · Series B · $330M · led by TCGX, ARCH Venture Partners17 Sep 2025 · Launch financing · $100M · led by ARCH Venture Partners, Mubadala, Monograph CapitalSeries B · $330MVenture · $100M
Funding history: 2 rounds from 17 Sep 2025 to 24 Jun 2026, $430M equity disclosed. Earlier rounds exist but are not sourced.17 Sep 2025: Launch financing, $100M; 24 Jun 2026: Series B, $330M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’23Q42026Q2Q3Q4Equity round24 Jun 2026 · Series B · $330M · led by TCGX, ARCH Venture Partners17 Sep 2025 · Launch financing · $100M · led by ARCH Venture Partners, Mubadala, Monograph Capital$330M$100M

Funding history 2 rounds · 3 sources · newest first

Earlier rounds not yet sourced. Ollin Biosciences was founded in 2023 and raised before 17 Sep 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series B
    Amount$330M
    Post-money—
    ✓ Confirmed
    Lead
    TCGX, ARCH Venture Partners
    Also
    Andreessen Horowitz, Blackstone, Commodore Capital, CPP Investments, RA Capital Management, T. Rowe Price, Mubadala, Monograph Capital
    Note
    Oversubscribed; an unnamed sovereign wealth fund and other unnamed institutional investors also participated. Earlier financing amounts not disclosed.
    Sources
  2. Launch financing
    Amount$100M
    Post-money—
    ✓ Confirmed
    Lead
    ARCH Venture Partners, Mubadala, Monograph Capital
    Note
    Company emerged from stealth with $100M. BioPharma Dive says ARCH, Mubadala Capital and Monograph co-led; BioSpace says a group led by ARCH, with Mubadala and Monograph participating. Neither states a round label (aggregators call it a Series A, not used as a source). No company press release could be reached.
    Sources
  3. Earlier rounds not yet sourced

Investors 10

  • ARCH Venture Partners2
  • Monograph Capital2
  • Mubadala2
  • TCGX1
  • Andreessen Horowitz
  • Blackstone
  • Commodore Capital
  • CPP Investments
  • RA Capital Management
  • T. Rowe Price

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the Austin hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Ollin Biosciences and its logo are trademarks of their owners, used here for identification only.